PRVB Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2023 @ 23:00):

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases...

Stats
Šios dienos apimtis	9.12M
Vidutinė apimtis	2.84M
Rinkos kapitalizacija	2.38B
EPS	$0 ( 2024-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.43
ATR14	$0.594 (2.38%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Sessa Capital (master), L.p.	Sell	15 567 497	Common Stock
2023-04-27	Wysenski Nancy	Sell	128 981	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	22 200	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	23 000	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	33 000	Option to Purchase Common Stock

INSIDER POWER
-62.73
Last 100 transactions
Buy: 11 373 023 \| Sell: 48 540 195

Tūris Koreliacija

Ilgas: 0.34 (neutral)

Trumpas: 0.37 (neutral)

Signal:(80.187) Neutral

Provention Bio Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
KRBP	0.886
RICO	0.879
NETE	0.825
MMAC	0.812
LWAC	0.809

10 Labiausiai neigiamai susiję koreliacijos
SQBG	-0.875
TCAC	-0.873
TCACU	-0.869
RMRM	-0.85
SVAC	-0.82
TLGT	-0.819

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Provention Bio Inc Koreliacija - Valiuta/Žaliavos

0.13
( neutral )

0.68
( moderate )

0.57
( weak )

0.45
( neutral )

-0.82
( strong negative )

-0.14
( neutral )

Provention Bio Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$12.90M
Bruto pelnas:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2022
Pajamos:	$12.90M
Bruto pelnas:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2021
Pajamos:	$1.40M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.810

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.880

Financial Reports:

No articles found.

Provention Bio Inc

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.